Effect of Chemotherapy on Tumor Marker (Ca 15.3) and Serum in Breast Cancer Patients of Southern Eastern Region of Chhattisgarh; 6 Years Follow up Study

2016 ◽  
Vol 3 (1) ◽  
pp. 16
Author(s):  
Priyanka Chandel ◽  
Harish Uraon ◽  
Vivek Choudhary
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Eastern Region ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Follow Up Study

Longitudinal follow-up of breast cancer patients with the tumor markers CA 549 and CA 15.3

1995 ◽  
Vol 10 (1) ◽  
pp. 30-34 ◽  
Author(s):  
L. Vankrieken ◽  
F. Heureux ◽  
J. Longueville ◽  
R. De Hertogh
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Clinical Situation ◽  
Breast Cancer Patients ◽  
Significant Information ◽  
Ca 15.3 ◽  
Cutoff Levels

In order to verify the efficiency of the tumor markers CA 15.3 and CA 549 in the follow-up of breast cancer patients, it was necessary first to check the cutoff levels of each tumor marker in women with an increased age-related risk, but with no evidence of disease. From 132 serum samples in this age group, we confirmed the CA 549 cutoff level of 12.1 U/ml. However, the cutoff of CA 15.3 was 34 U/ml, which is higher than previously reported in the literature. Fifty-two breast cancer patients with or without metastases at the time of entry into the study were followed for 2 to 3 years with both tumor markers. The sensitivity, specificity and the test efficiency for the presence of metastases were analyzed with each tumor marker. Taking into account the different cutoff levels, we concluded that both tumor markers can be used independently to follow the clinical situation of patients. In several cases an increase in both tumor markers was observed before a clinical diagnosis of metastases could be made. Combination of these two tumor markers gave no more significant information about the patient's clinical situation than each tumor marker alone.

Analytical and clinical evaluation of a new tumor marker in breast cancer: CA 27.29

1992 ◽  
Vol 7 (1) ◽  
pp. 43-46 ◽  
Author(s):  
M. Correale ◽  
I. Abbate ◽  
G. Gargano ◽  
A. Catino ◽  
C.D. Dragone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Breast Disease ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Lower Specificity ◽  
Apparently Healthy

Evaluation of a radioimmunoassay for a new tumor marker, named CA 27.29, recently proposed for use in breast cancer patients, is reported in this study. After considering the analytical performance, the clinical study was directed to a control group of 66 apparently healthy subjects (Controls), a group of 25 women with benign breast disease (BBD) and a group of 164 breast cancer patients divided into primary before any treatment (M-), in follow-up with no evidence of disease (NED) and presence of metastases (M+). When compared to CA 15.3, our results showed similar sensitivity of both markers with a slightly lower specificity for CA 27.29. In some cases, however, CA 27.29 elevation appears earlier than CA 15.3 as a sign of metastases. We thus propose their associated use.

Interleukin-10 Levels are Associated with Doxorubicin-Related Cardiotoxicity in Breast Cancer Patients in a One-Year Follow-Up Study

2021 ◽  
pp. 1-16
Author(s):  
Michelle Teodoro Alves ◽  
Ricardo Simões ◽  
Rodrigo Mendonça Cardoso Pestana ◽  
Angélica Navarro de Oliveira ◽  
Heloísa Helena Marques Oliveira ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Interleukin 10 ◽  
Breast Cancer Patients ◽  
Follow Up Study ◽  
One Year

scholarly journals Arm lymphoedema and upper limb impairments in sentinel node-negative breast cancer patients: A one year follow-up study

The Breast ◽  
2016 ◽  
Vol 29 ◽  
pp. 102-108 ◽  
Author(s):  
An De Groef ◽  
Marijke Van Kampen ◽  
Elena Tieto ◽  
Petra Schönweger ◽  
Marie-Rose Christiaens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Upper Limb ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Follow Up Study ◽  
Node Negative Breast Cancer ◽  
Arm Lymphoedema ◽  
One Year

Ca 15.3 as a Tumour Marker in Breast Cancer

1987 ◽  
Vol 2 (3) ◽  
pp. 135-142 ◽  
Author(s):  
Peter Schmidt-Rhode ◽  
Klaus-Dieter Schulz ◽  
Gerhard Sturm ◽  
Anette Raab-Frick ◽  
Helge Prinz
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Tumour Marker ◽  
Primary Treatment ◽  
Breast Diseases ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Healthy Females

CA 15.3 is an antigenic determinant associated with human mammary carcinomas. Two murine monoclonal antibodies have been raised against the determinants, and an immunoradiometric assay (IRMA-Kit, Centocor, USA) has been developed to determine the antigen levels in plasma of cancer patients. Based on the 99% confidence limit of healthy women, plasma values above 30 U/ml are considered abnormal. Plasma samples from 357 women were examined in the present study. Healthy females (n = 84) ranged below the cut-off level between < 10 and 29 U/ml. Higher values were found in 12.5% of benign breast diseases and in 23.6% of breast cancer patients, including all stages. Depending on the stage of the disease, there were elevated levels in 11% of operable breast cancer patients preoperatively, in 7% of the cases with no evidence of disease after primary treatment and in 63.5% ofpatients with disseminated mammary carcinoma. In metastasized breast cancer the frequency and the degree of abnormal titers were closely related to the extent of the metastatic disease. Follow-up examinations of 63 patients under cytotoxic therapy showed CA 15.3 changes correlating well with the clinical course in up to 90% of the antigen positive cases. The present data indicate that CA 15.3 may be useful in the surveillance of breast cancer patients. However in our study one third of the patients with metastatic breast cancer did not show any increase in CA 15.3 and must be regarded as antigen negative.

Sign in / Sign up

Export Citation Format

Share Document